Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.